BRAF addiction of thyroid cancers makes them therapeutically vulnerable

November 21, 2011

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine (RAI). A team of researchers led by James Fagin, at Memorial Sloan-Kettering Cancer Center, New York, has now identified a way to potentially exploit the expression of BRAF by such cancers for therapeutic purposes.

Despite the prevalence of BRAF mutations in papillary carcinoma it has remained unclear how dependent thyroid cancers are on BRAF expression. Fagin and colleagues first showed that thyroid tumors in mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas were exquisitely dependent on BRAF for viability. Of therapeutic significance, treating thyroid tumor-bearing mice with drugs that inhibited the BRAF signaling pathway rendered the tumor cells susceptible to a therapeutic dose of RAI. Fagin and colleagues therefore suggest that their data provide rationale for clinical trials testing whether such drugs can restore the efficacy of RAI therapy in patients with papillary thyroid carcinomas expressing BRAF mutations.
-end-
TITLE: Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

AUTHOR CONTACT:
James A. Fagin
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Phone: 646-888-2136; Fax: 646-422-0890; E-mail: faginj@mskcc.org.

JCI Journals

Related Thyroid Cancer Articles from Brightsurf:

Trends in the global burden of thyroid cancer
This study examined the worldwide trends of thyroid cancer from 1990 to 2017 according to geographic location, sex, age and socioeconomic factors.

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Thyroid cancer, genetic variations, cell phones linked in YSPH study
Radiation from cell phones is associated with higher rates of thyroid cancer among people with genetic variations in specific genes, a new study led by the Yale School of Public Health finds.

AJR researchers take step toward automating thyroid cancer triage
An article published ahead-of-print in the April issue of the American Journal of Roentgenology (AJR) details how a Stanford University team developed a quantitative framework able to sonographically differentiate between benign and malignant thyroid nodules at a level comparable to that of expert radiologists, which could provide second-opinion malignancy risk estimation to clinicians and ultimately help decrease the number of unnecessary biopsies and surgical procedures.

Thyroid cancer rates in US
An analysis suggests rates of thyroid cancer in the US appear to have plateaued in recent years after decades on the rise.

Using artificial intelligence to predict risk of thyroid cancer on ultrasound
New study uses machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

For low-risk thyroid cancer patients, less may be more for post-surgery surveillance
Patient self-advocacy is important, and although a maximizing preference may be advantageous in many situations, new research led by the University of Michigan Rogel Cancer Center shows that, in the case of long-term surveillance of treated, low-risk thyroid cancer, health care ''maximizers'' consume more health care resources -- such as doctor visits and diagnostic imaging tests -- which drive up costs without a clear improvement in outcomes.

New test for thyroid cancer could prevent unnecessary surgery
Each year, thanks to inconclusive tests for thyroid cancer, thousands of people undergo unnecessary surgeries to remove part or all of their thyroids.

Raman spectroscopy poised to make thyroid cancer diagnosis less invasive
Researchers have demonstrated that an optical technique known as Raman spectroscopy can be used to differentiate between benign and cancerous thyroid cells.

Are doctors treating more thyroid cancer patients than necessary?
New research may help change treatment practices for patients diagnosed with low risk thyroid cancer.

Read More: Thyroid Cancer News and Thyroid Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.